Affordable Access

deepdyve-link
Publisher Website

MLC601 in vascular dementia: an efficacy and safety pilot study.

Authors
  • Pakdaman, Hossein1
  • Amini Harandi, Ali1
  • Gharagozli, Koroush1
  • Abbasi, Mehdi1
  • Ghaffarpour, Majid2
  • Ashrafi, Farzad1
  • Delavar Kasmaei, Hosein1
  • Amini Harandi, Asghar3
  • 1 Brain Mapping Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. , (Iran)
  • 2 Iranian Center of Neurological Research, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran. , (Iran)
  • 3 Department of Biochemistry, School of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran. , (Iran)
Type
Published Article
Journal
Neuropsychiatric Disease and Treatment
Publisher
Dove Medical Press
Publication Date
Jan 01, 2017
Volume
13
Pages
2551–2557
Identifiers
DOI: 10.2147/NDT.S145047
PMID: 29042785
Source
Medline
Keywords
License
Unknown

Abstract

Patients treated with MLC601 over the 2 years showed dramatically better cognitive outcome compared with those treated with placebo. MLC601 was devoid of any serious adverse events and was well-tolerated.

Report this publication

Statistics

Seen <100 times